Read E.V.I.dently Today for current news about health policy and events, among other topics.
E.V.I.dently Today Blog
Paying for prescription medicines based on their value to patients is increasingly seen as a promising technique to combat rising medication costs. But while other parts of the health care sector are moving rapidly toward value-based arrangements, why are biopharmaceutical manufacturers and payers holding back? NPC's new white paper identifies four regulations that need changes or clarification before we can begin connecting price to value for prescription drugs.
During a webinar hosted by the Integrated Benefits Institute on March 5, Chuck Reynolds, consultant for Benfield, a Division of Gallagher Benefit Services, and Kristen Putnam, Director, Global Benefits, for Praxair, discussed the challenges facing employers in working with their pharmaceutical benefit managers (PBMs) and what steps employers can take to better manage those relationships.
A new infographic based on a National Pharmaceutical Council peer-reviewed study explains how gaps between upfront costs and long-term savings of innovative treatments can emerge, why we need to close these gaps and how we can work to eliminate them.
National Pharmaceutical Council President Dan Leonard in Specialty Pharmacy Times: How Do We Pay for Medical Innovation?
In this month's Specialty Pharmacy Times, National Pharmaceutical Council President Dan Leonard says it’s time to think differently about how we pay for health care and assess value and benefits.
In a column published in Morning Consult, NPC Chief Science Officer and Executive Vice President Robert W. Dubois, MD, PhD, explains that asking why drug spending is so high assumes that spending more money on drugs is a bad thing, confusing drug spending with overall health care spending.
February 28 is Rare Disease Day, highlighting both the progress made to date in developing treatments for rare diseases, as well as how much work remains to be done. Nearly one in 10 Americans suffers from a rare disease, and more than half of those are children. There are more than 7,000 rare diseases and only approximately 450 FDA-approved medical treatments, according to the National Organization for Rare Disorders.